AI
KRON

Acuitas Investments’s Kronos Bio KRON Stock Holding History

Acuitas Investments’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-554,500
Closed -$554K – 95
2024
Q3 		$554K Buy
554,500
+111,043
+25% +$123K 0.25% 98
2024
Q2 		$550K Buy
443,457
+2,351
+0.5% +$2.39K 0.29% 94
2024
Q1 		$573K Buy
441,106
+113,130
+34% +$129K 0.29% 95
2023
Q4 		$410K Sell
327,976
-845
-0.3% -$935 0.21% 104
2023
Q3 		$427K Sell
328,821
-12
-0% -$19 0.25% 89
2023
Q2 		$566K Buy
+328,833
New +$522K 0.33% 79

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acuitas Investments's KRON Position: Q4 2024 in Review

Acuitas Investments sold out of Kronos Bio (KRON) in Q4 2024, closing a stake of 554,500 shares — an estimated $554K sold.

Acuitas Investments first reported a position in KRON in Q2 2023 and held it in 6 quarters. The position peaked at $573K in Q1 2024. 56 funds tracked by Wall St. Rank hold KRON as of Q4 2024.

  • Acuitas Investments reported no remaining Kronos Bio position as of Q4 2024 after selling out during the quarter.
  • Acuitas Investments sold 554,500 Kronos Bio shares in Q4 2024, an estimated $554K.
  • Acuitas Investments first reported a position in Kronos Bio in Q2 2023 and held it in 6 quarters.
  • Acuitas Investments's Kronos Bio position peaked at $573K in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.